Surgery is a key treatment for Triple-Negative Breast Cancer (TNBC), particularly in the early stages. The type of surgery depends on the tumour's size, location, and extent of spread.
For many patients with early-stage TNBC, chemotherapy is given before surgery to reduce tumour size, making breast-conserving surgery more feasible and improving treatment outcomes.
Radiation therapy is commonly recommended after breast surgery to destroy any remaining cancer cells that cannot be seen during surgery, helping lower the risk of the disease returning.
After a lumpectomy to reduce the chance of recurrence.
After a mastectomy for larger tumours or when cancer has spread to nearby lymph nodes.
Chemotherapy and Neoadjuvant Chemotherapy
Chemotherapy remains a cornerstone in the treatment of triple-negative breast cancer (TNBC), as these rapidly dividing cancer cells often respond well to anti-cancer medicines.
- Neoadjuvant Chemotherapy (Before Surgery): Administered before surgery to reduce tumour size, improve the chances of breast-conserving surgery, and assess how effectively the cancer responds to treatment. Achieving a pathologic complete response (pCR) is generally linked to better long-term outcomes.
- Adjuvant Chemotherapy (After Surgery): Given after surgery to destroy any remaining cancer cells and lower the risk of recurrence.
- Commonly Used Medicines: Treatment may include anthracyclines (doxorubicin), taxanes (paclitaxel, docetaxel), and platinum-based agents (carboplatin, cisplatin), particularly for patients with BRCA1/BRCA2 mutations.
Neoadjuvant chemotherapy is now widely regarded as a preferred treatment approach for many patients with TNBC, as it can reduce tumour size before surgery and improve the likelihood of successful surgical outcomes. Mayo Clinic (2024).
Targeted Therapy
Targeted therapy is opening new possibilities for treating TNBC by focusing on specific genetic changes within cancer cells, even though this breast cancer subtype lacks hormone and HER2 receptors.
- PARP Inhibitors: Patients with BRCA1 or BRCA2 gene mutations may benefit from PARP inhibitors such as Olaparib (Lynparza) and Talazoparib (Talzenna). These medicines prevent cancer cells from repairing damaged DNA, helping to slow tumour growth.
- Antibody-Drug Conjugates (ADCs): ADCs combine a targeted antibody with a cancer-fighting drug, delivering treatment directly to tumour cells while reducing damage to healthy tissue. Sacituzumab Govitecan (Trodelvy) is a leading example that targets the Trop-2 protein, offering an effective treatment option for patients with advanced TNBC. (Breastcancer.org, 2025).
Immunotherapy
Immunotherapy helps the body's immune system recognise and destroy triple-negative breast cancer (TNBC) cells. It has become an important treatment option for certain patients, especially when combined with chemotherapy.
- Checkpoint Inhibitors: Drugs such as Pembrolizumab (Keytruda) block the PD-1/PD-L1 pathway, enabling immune cells to attack cancer more effectively. They are commonly used for eligible patients with advanced or high-risk early-stage TNBC.
- Research in Progress: Current clinical studies are exploring new combinations of immunotherapy with chemotherapy, targeted medicines, and cancer vaccines to further improve treatment outcomes and long-term survival. (Wiley Online Library, 2024).
Combination Therapies and Future Directions:
The future of TNBC treatment lies in combining chemotherapy, immunotherapy, and targeted therapies to improve patient outcomes. Advances in genomic profiling are also enabling more personalised treatment decisions based on each tumour's unique genetic profile. (MDPI, 2024).
Are New Treatments Available for Triple-Negative Breast Cancer?
Yes. Advances in TNBC research are expanding treatment options, particularly for patients with advanced disease. Antibody-drug conjugates (ADCs) such as
Trodelvy (sacituzumab govitecan) and Datroway (datopotamab deruxtecan) have shown encouraging clinical benefits by delivering targeted therapy directly to cancer cells.
Breast Cancer Research Foundation
Researchers are also exploring new approaches, including immunotherapy combinations, PARP inhibitors for patients with BRCA mutations, and personalised cancer vaccines designed to strengthen the body's immune response against TNBC.
ASCOPubs
Together, these innovations are driving more precise and effective treatments, improving outcomes and offering renewed hope for people living with triple-negative breast cancer. Breast Cancer Research Foundation.
Other Advancements in TNBC Treatment:
Research into triple-negative breast cancer is opening new possibilities for more precise and effective care. Some of the most promising developments include:
- Liquid Biopsies: Blood-based tests that detect circulating tumour DNA (ctDNA), helping doctors monitor treatment response and identify recurrence earlier with minimal invasiveness.
- Next-Generation Targeted Therapies: Investigational drugs targeting pathways such as PI3K/AKT/mTOR and androgen receptors are showing potential in selected TNBC subtypes.
- Cancer Vaccines: Novel immunotherapies are being developed to train the immune system to recognise and destroy TNBC cells more effectively.
- Combination Treatment Strategies: Researchers are evaluating combinations of chemotherapy, immunotherapy, and targeted therapies to improve outcomes while limiting treatment-related side effects.
- Precision Medicine: Advances in genomic testing are enabling more personalised treatment plans by matching therapies to the unique genetic characteristics of each patient's tumour.
Conclusion & Future Perspectives:
Triple-negative breast cancer (TNBC) is one of the more aggressive types of breast cancer and can be difficult to treat because it does not respond to hormone therapy or HER2-targeted treatments. However, recent medical advances are bringing new hope to patients.
- Early Detection and Genetic Testing: Finding TNBC early and understanding its genetic makeup can help doctors choose the most effective treatment for each patient.
- New Treatment Options: Treatments such as immunotherapy, PARP inhibitors, and newer targeted medicines like Trodelvy and Datroway are improving outcomes, especially for patients with advanced TNBC.
- Personalised Care: Doctors are increasingly combining chemotherapy, targeted therapies, and immunotherapy to create treatment plans tailored to each patient's condition. This approach can improve treatment success while helping reduce side effects.
With continuous research and new medical breakthroughs, the future of TNBC treatment is becoming more personalised and effective. These advances are giving patients better treatment options, improved survival, and greater hope for a healthier future.
Take Charge of Your Health Today:
Finding triple-negative breast cancer early can make a big difference. Getting the right treatment from experienced doctors is equally important.
At Amrita Hospital, Faridabad, our team of oncologists, surgeons, and cancer specialists works together to create a treatment plan that is tailored to your individual needs. We use advanced treatment options and modern technology to provide the best possible care.
Don't ignore any breast changes. Book your consultation today and take the first step towards timely diagnosis, effective treatment, and better health.
Frequently Asked Questions:
What is the life expectancy of someone with triple-negative breast cancer?
Life expectancy depends on how early the cancer is found, the stage of the disease, and how well the treatment works. People diagnosed at an early stage often have good outcomes, while advanced or metastatic TNBC is more difficult to treat.
How quickly can triple-negative breast cancer come back?
Triple-negative breast cancer is more likely to return within the first 3 to 5 years after treatment. This is why regular check-ups and follow-up care are very important.
What is the last stage of triple-negative breast cancer?
The last stage is Stage IV (metastatic TNBC). At this stage, the cancer has spread from the breast to other parts of the body, such as the lungs, liver, bones, or brain.
Where does triple-negative breast cancer usually spread first?
It often spreads first to the nearby lymph nodes under the arm. If the disease progresses, it may spread to the lungs, liver, bones, or brain.
Can triple-negative breast cancer be cured?
Yes, many people can successfully recover, especially when the cancer is found early and treated quickly. Treatment may include surgery, chemotherapy, radiation therapy, immunotherapy, or targeted therapy. Regular follow-up visits are important to detect any signs of recurrence as early as possible.
References:
